Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas

International Journal of Cancer

Volumn 138, Issue 5, 2016, Pages 1269-1280

  Albrecht, Valerie ^a   Richter, Antonia ^b   Pfeiffer, Sarah ^a   Gebauer, Michaela ^b   Lindner, Simon ^a   Gieser, Eugenie ^a   Schüller, Ulrich ^a   Schichor, Christian ^a   Gildehaus, Franz Josef ^a   Bartenstein, Peter ^a   Tonn, Jörg Christian ^a   Skerra, Arne ^b   Glass, Rainer ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

brain tumor diagnosis; immunohistochemistry; lipocalin; molecular imaging tracer; oncofetal fibronectin; protein engineering; protein scaffold

Indexed keywords

ANTICALIN; FIBRONECTIN; FIBRONECTIN EXTRA DOMAIN B; IODINE 123; TRACER; UNCLASSIFIED DRUG; ANTIBODY; CD31 ANTIGEN; LIPOCALIN; ONCOFETAL FIBRONECTIN; PEPTIDE LIBRARY; PROTEIN BINDING;

ARTICLE; ASTROCYTOMA; AUTORADIOGRAPHY; BRAIN BIOPSY; CANCER DIAGNOSIS; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MOLECULAR IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; BRAIN NEOPLASMS; CHEMISTRY; IMMUNOLOGY; METABOLISM; PEPTIDE LIBRARY; PROCEDURES; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANTIBODIES; ANTIGENS, CD31; BRAIN NEOPLASMS; CELL LINE, TUMOR; FIBRONECTINS; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOCALINS; MOLECULAR IMAGING; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 84955688469     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29874     Document Type: Article

References (36)

1. Louis DN, Ohgaki H, Wiestler OD, et al., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Dolecek TA, Propp JM, Stroup NE, et al., CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology 2012; 14 Suppl 5: v1-v49.
3. Crocetti E, Trama A, Stiller C, et al., Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 2012; 48: 1532-42.
4. Kreth FW, Thon N, Simon M,.; for the German Glioma Network. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 2013; 24: 3117-23.
5. Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
6. Stupp R, Hegi M, Weller M., Neuro-oncology, a decade of temozolomide and beyond. Expert Rev Anticancer Ther 2010; 10: 1675-7.
7. Norden AD, Drappatz J, Wen PY., Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5: 610-20.
8. Van Meir EG, Hadjipanayis CG, Norden AD, et al., Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166-93.
9. Gilbert MR, Dignam JJ, Armstrong TS, et al., A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 699-708.
10. Chinot OL, Wick W, Mason W, et al., Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370: 709-22.
11. Chowdhary S, Chamberlain M., Bevacizumab for the treatment of glioblastoma. Expert Rev Neurother 2013; 13: 937-49.
12. Taal W, Oosterkamp HM, Walenkamp AM, et al., Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 2014; 15: 943-53.
13. Rinne ML, Lee EQ, Nayak L, et al., Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs 2013; 18: 137-53.
14. Hygino da Cruz LC, Jr, Rodriguez I, Domingues RC, et al., Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011; 32: 1978-85.
15. la Fougere C, Suchorska B, Bartenstein P, et al., Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol 2011; 13: 806-19.
16. Meier R, Braren R, Kosanke Y, et al., Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins. PLoS One 2014; 9: e94972.
17. 131I-SIP(L19), a marker of angiogenesis. J Nucl Med 2007; 48: 608-14.
18. Gebauer M, Schiefner A, Matschiner G, et al., Combinatorial design of an Anticalin directed against the extra-domain B for the specific targeting of oncofetal fibronectin. J Mol Biol 2013; 425: 780-802.
19. Gebauer M, Skerra A., Anticalins: small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol 2012; 503: 157-88.
20. Richter A, Eggenstein E, Skerra A., Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett 2014; 588: 213-8.
21. Mendler CT, Skerra A., Anticalins: An emerging class of novel biologics to treat cancer and other severe diseases. Drug Future 2013; 38: 169-179.
22. 89Zr-PRS-110 PET tracer. J Nucl Med 2014; 55: 665-71.
23. Schiefner A, Skerra A., The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds. Acc Chem Res 2015; 48: 976-85.
24. Neri D, Bicknell R., Tumour vascular targeting. Nat Rev Cancer 2005; 5: 436-46.
25. 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009; 113: 2265-74.
26. Castellani P, Borsi L, Carnemolla B, et al., Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 2002; 161: 1695-700.
27. Schmidt TG, Skerra A., The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat Protoc 2007; 2: 1528-35.
28. Fraker PJ, Speck JC, Jr., Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-57.
29. Parums DV, Cordell JL, Micklem K, et al., JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990; 43: 752-7.
30. Serres E, Debarbieux F, Stanchi F, et al., Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice. Oncogene 2014; 33: 3451-62.
31. Santimaria M, Moscatelli G, Viale GL, et al., Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003; 9: 571-9.
32. Borsi L, Balza E, Bestagno M, et al., Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002; 102: 75-85.
33. Castellani P, Viale G, Dorcaratto A, et al., The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994; 59: 612-8.
34. Chen S, Chakrabarti R, Keats EC, et al., Regulation of vascular endothelial growth factor expression by extra domain B segment of fibronectin in endothelial cells. Invest Ophthalmol Vis Sci 2012; 53: 8333-43.
35. Carnemolla B, Neri D, Castellani P, et al., Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 1996; 68: 397-405.
36. Korshunov A, Meyer J, Capper D, et al., Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 2009; 118: 401-5.